A randomised, double blind, placebo controlled, parallel study to assess the benefits of aclidinium bromide in the relief of COPD symptoms including cough when administered to patients with COPD

Trial Profile

A randomised, double blind, placebo controlled, parallel study to assess the benefits of aclidinium bromide in the relief of COPD symptoms including cough when administered to patients with COPD

Completed
Phase of Trial: Phase IV

Latest Information Update: 24 May 2017

At a glance

  • Drugs Aclidinium bromide (Primary)
  • Indications Bronchitis; Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Acronyms M-34273-46
  • Sponsors AstraZeneca
  • Most Recent Events

    • 24 May 2017 Results of a post-hoc analysis assessing the efficacy of aclidinium bromide on cough-related endpoints in symptomatic patients with moderate COPD, stratified according to cough severity, presented at the 113th International Conference of the American Thoracic Society.
    • 24 May 2017 Primary endpoint has been met. (Change From Baseline in Overall Exacerbations of Chronic Pulmonary Disease Tool-Respiratory Symptoms (E-RS) Total Score Over the 8 Week Study Period), as reported in an abstract presented at the 113th International Conference of the American Thoracic Society
    • 24 May 2017 Results presented at the 113th International Conference of the American Thoracic Society
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top